MARKET

ALXN

ALXN

Alexion Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

150.06
-0.04
-0.03%
After Hours: 151.25 +1.19 +0.79% 18:19 03/08 EST
OPEN
149.29
PREV CLOSE
150.10
HIGH
151.11
LOW
149.17
VOLUME
3.20M
TURNOVER
--
52 WEEK HIGH
162.60
52 WEEK LOW
72.67
MARKET CAP
32.99B
P/E (TTM)
55.70
1D
5D
1M
3M
1Y
5Y
Alexion Pharmaceuticals Inc. stock outperforms market despite losses on the day
Shares of Alexion Pharmaceuticals Inc. sank 0.03% to $150.06 Monday, on what proved to be an all-around mixed trading session for the stock market, with the...
marketwatch.com · 3h ago
Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report?
Zacks.com · 2d ago
Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report?
Zacks.com · 2d ago
Alexion Pharmaceuticals Inc. stock rises Friday, still underperforms market
Shares of Alexion Pharmaceuticals Inc. rallied 1.10% to $150.10 Friday, on what proved to be an all-around favorable trading session for the stock market,...
marketwatch.com · 3d ago
Vertex Stock Fell After a Setback on a New Drug. It’s an Opportunity for Investors.
The biotech’s cystic fibrosis franchise remains strong, and its pipeline looks promising
Barrons.com · 3d ago
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market By Development, Trends, Investigation 2020 And Forecast To 2026
Mar 05, 2021 (Market Insight Reports) -- A recent report provides crucial insights along with application based and forecast information in the Global...
Market Insight Reports · 3d ago
Alexion Pharmaceuticals Inc. stock outperforms market on strong trading day
Shares of Alexion Pharmaceuticals Inc. inched 0.18% higher to $148.46 Thursday, on what proved to be an all-around poor trading session for the stock market,...
marketwatch.com · 4d ago
Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that three abstracts have been accepted for presentation at the 73rd annual meeting of the American Academy of Neurology (AAN), taking place virtually from April 17 through April 22, 2021. New rea...
BusinessWire · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALXN. Analyze the recent business situations of Alexion Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALXN stock price target is 172.65 with a high estimate of 196.00 and a low estimate of 140.00.
EPS
Institutional Holdings
Institutions: 1.18K
Institutional Holdings: 207.51M
% Owned: 94.39%
Shares Outstanding: 219.85M
TypeInstitutionsShares
Increased
236
13.57M
New
252
11.05M
Decreased
277
28.77M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.16%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Independent Director
David Brennan
Chief Executive Officer/Director
Ludwig Hantson
Chief Financial Officer/Executive Vice President
Aradhana Sarin
Executive Vice President/Chief Compliance Officer
Indrani Franchini
Executive Vice President/Secretary
Ellen Chiniara
Executive Vice President
Tanisha Carino
Executive Vice President
Brian Goff
Executive Vice President
John Orloff
Independent Director
Christopher Coughlin
Other
Becky Lillie
Independent Director
Deborah Dunsire
Other
Uzair Qadeer
Independent Director
Paul Friedman
Independent Director
John Mollen
Independent Director
Francois Nader
Independent Director
Judith Reinsdorf
Independent Director
Andreas Rummelt
No Data
About ALXN
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.

Webull offers kinds of Alexion Pharmaceuticals, Inc. stock information, including NASDAQ:ALXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALXN stock methods without spending real money on the virtual paper trading platform.